Pharmacosimilars In Obesity Medicine: Informed Choice, Appropriate Choice

Abstract

Newer development in endocrine pharmacology have
blurred the distinction between biosimilars and generics.
The originator semaglutide, for example, is a biologically
active compound, but later versions are chemically
synthesized generics. Tirzepatide is a synthetic
polypeptide. These molecules are marketed in different
strengths and delivery devices across the world. The word
‘pharmaco-similar’ can be used to describe both
biosimilar and generic versions of originator peptidebased
medications. This communication suggests a
useful framework which assists in sharing information
and reaching an informed decision regarding choice of
anti-obesity medication. This approval process and status,
evidence and experience base, economic factors, rules
related to interchange/substitution, robustness of cold
chain, and availability of uninterrupted supply all
influence this decision.
Keywords: Biosimilar, diabetes, generic, GIPRA, GLP1RA,
liraglutide, obesity, semaglutide, tirzepatide